Holland Shelby M, Sohal Amrik, Nand Alka Ashwini, Hutmacher Dietmar W
Department of Management, Monash Business School, Monash University Caufield Campus, Melbourne, VIC, Australia.
Australian Research Council Training Centre for Cell and Tissue Engineering Technologies, Monash University Clayton Campus, Melbourne, VIC, Australia.
Front Bioeng Biotechnol. 2024 Aug 8;12:1413688. doi: 10.3389/fbioe.2024.1413688. eCollection 2024.
Advancements in cell therapy have the potential to improve healthcare accessibility for eligible patients. However, there are still challenges in scaling production and reducing costs. These challenges involve various stakeholders such as the manufacturing facility, third-party logistics (3PL) company, and medical center. Proposed solutions tend to focus on individual companies rather than addressing the interconnectedness of the supply chain's challenges. The challenges can be categorized as barriers from product characteristics, regulatory requirements, or lagging infrastructure. Each barrier affects multiple stakeholders, especially during a boundary event like product handover. Therefore, solutions that only consider the objectives of one stakeholder fail to address underlying problems. This review examines the interconnecting cell therapy supply chain challenges and how they affect the multiple stakeholders involved. The authors consider whether proposed solutions impact individual stakeholders or the entire supply chain and discuss the benefits of stakeholder coordination-focused solutions such as integrated technologies and information tracking. The review highlights how coordination efforts allow for the implementation of widely-supported cell therapy supply solutions such as decentralized manufacturing through stakeholder collaboration.
细胞治疗的进展有可能改善符合条件的患者获得医疗保健的机会。然而，在扩大生产规模和降低成本方面仍然存在挑战。这些挑战涉及多个利益相关者，如生产设施、第三方物流（3PL）公司和医疗中心。提议的解决方案往往侧重于个别公司，而不是解决供应链挑战的相互关联性。这些挑战可分为产品特性、监管要求或基础设施滞后等障碍。每个障碍都会影响多个利益相关者，尤其是在产品交接等边界事件期间。因此，仅考虑一个利益相关者目标的解决方案无法解决潜在问题。本综述探讨了细胞治疗供应链相互关联的挑战以及它们如何影响所涉及的多个利益相关者。作者考虑提议的解决方案是影响个别利益相关者还是整个供应链，并讨论以利益相关者协调为重点的解决方案（如集成技术和信息跟踪）的好处。该综述强调了协调努力如何通过利益相关者合作实现广泛支持的细胞治疗供应解决方案，如分散式生产。
